Cancerify Logo
Log inSign up
Back to clinical trials
RecruitingInterventionalPhase 1/Phase 2

AN INTERVENTIONAL PHASE 1B/2 STUDY TO EVALUATE THE SAFETY AND EFFICACY OF PF-08634404 MONOTHERAPY AND IN COMBINATION WITH OTHER ANTICANCER AGENTS IN ADULT PARTICIPANTS WITH LOCALLY ADVANCED OR METASTATIC RENAL CELL CARCINOMA

NCT ID: NCT07227415Sponsor: PfizerLast updated: 2026-06-04

Summary

This study is testing a new medicine called PF-08634404 and how it works in adults with advanced Renal Cell Carcinoma (RCC)- a type of kidney cancer that is either locally advanced (spread to nearby tissues) or metastatic (spread to other parts of the body). The study will look at the safety of the study medicine, when given alone or with other anticancer medicines, and how this type of cancer responds to them. To join the study, participants must be adults; with locally advanced or metastatic RCC; who have not received treatment for their advanced kidney cancer. Participants will receive study medicine either alone or with other anticancer medicines. The medicine will be given through intravenous (IV) infusions, which means it will be injected directly into a vein. All treatments will take place at clinical study sites, where trained medical staff will take care of participants during and after each visit.

Arms & interventions

  • DrugPF-08634404

    Concentrate for solution for infusion

  • DrugIpilimumab

    Solution for infusion

  • DrugAxitinib

    Tablet

Outcome measures

Primary

  • Confirmed objective response rate (ORR) using RECIST v1.1 as assessed by investigator

    ORR is defined as the proportion of participants in the analysis population having a best overall response (BOR) of confirmed complete response (CR) or confirmed partial response (PR) according to RECIST v1.1 as assessed by investigator.

    Time frame: Up to approximately 3 years

  • Number of Participants with Treatment Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)

    AEs as characterized by type, frequency, severity (as graded by NCI CTCAE version 5.0), timing, seriousness, and relationship to study intervention.

    Time frame: Through 90 days after the last study intervention (Up to approximately 3 years)

  • Number of participants with dose limiting toxicity (DLT)

    The number of participants who experienced DLTs during the DLT evaluation period in Cohort B (combination 1) and Cohort C (combination 2).

    Time frame: Though end of DLT evaluation period (Up to approximately 3 years)

Secondary

  • Duration of Response (DOR) per RECIST v1.1 by investigator

    Time frame: Up to approximately 3 years

  • Progression Free Survival (PFS) per RECIST v1.1 by investigator

    Time frame: Up to approximately 3 years

  • Overall Survival (OS)

    Time frame: Up to approximately 3 years

  • Number of Participants With Clinical Laboratory Abnormalities

    Time frame: Time from the date of first dose of study intervention through 30-37 days after last dose of study intervention (approximately 3 years)

  • Pharmacokinetics (PK): Serum concentration of PF-08634404

    Time frame: Up to 37 days after the last dose of treatment

  • Incidence of Anti-Drug Antibody (ADA) against PF-08634404

    Time frame: Up to 37 days after the last dose of treatment

Eligibility criteria

Sex: AllAge: 18 Years and olderHealthy volunteers: No
Inclusion Criteria: * 18 years of age or older at screening * Locally advanced (not amenable to curative surgery or radiation therapy) or metastatic RCC with diagnosis confirmed by histology/cytology * At least one measurable (as defined by the investigator) and untreated lesion * Adequate hematologic, hepatic, cardiac and renal function * No prior systemic therapy for RCC (immunotherapy after surgery is allowed if received \>12 months prior) * Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1. * All International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) based risk categories Exclusion Criteria: Participants may be excluded if they meet any of the following: * Known active brain lesions including leptomeningeal metastasis, brainstem, meningeal or spinal cord metastases or compression. * Clinically significant risk of haemorrhage or fistula * History of another malignancy within 3 years * History of allogeneic organ transplantation and allogeneic hematopoietic stem cell transplantation. * active autoimmune diseases requiring systemic treatment within the past 2 years * uncontrolled cardiac and other comorbidities within 6 months prior to the first dose * Major surgery or severe trauma within 4 weeks before the first dose, or planned major surgery during the study * History of severe bleeding tendency or coagulation dysfunction * History of oesophageal varices, severe ulcers, gastrointestinal perforation, abdominal fistula, gastrointestinal obstruction, intra-abdominal abscess or acute gastrointestinal bleeding within 6 months prior to the first dose * Acute, chronic or symptomatic infections * Participants with history of immunodeficiency

Study locations (101)

Mayo Clinic Building- Phoenix

Phoenix, Arizona, 85054

Not Yet Recruiting

Mayo Clinic

Scottsdale, Arizona, 85259

Not Yet Recruiting

Highlands Oncology Group

Fayetteville, Arkansas, 72703

Recruiting

Highlands Oncology Group

Rogers, Arkansas, 72758

Recruiting

Highlands Oncology Group

Springdale, Arkansas, 72762

Recruiting

City of Hope (City of Hope National Medical Center, City of Hope Medical Center)

Duarte, California, 91010

Recruiting

City of Hope Investigational Drug Services (IDS)

Duarte, California, 91010

Recruiting

UC San Diego Medical Center - Encinitas

Encinitas, California, 92024

Not Yet Recruiting

City of Hope Investigational Drug Services (IDS)

Irvine, California, 92618

Recruiting

City of Hope

Irvine, California, 92618

Recruiting

UC San Diego / Moores Cancer Center

La Jolla, California, 92037

Not Yet Recruiting

UC San Diego Koman Family Outpatient Pavilion

La Jolla, California, 92037

Not Yet Recruiting

UC San Diego Medical Center - La Jolla (Jacobs Medical Center / Thornton Pavilion)

La Jolla, California, 92037

Not Yet Recruiting

UC San Diego Sulpizio Cardiovascular Center

La Jolla, California, 92037

Not Yet Recruiting

City of Hope

Long Beach, California, 90813

Recruiting

UC San Diego Medical Center - Bankers Hill

San Diego, California, 92101

Not Yet Recruiting

UC San Diego McGrath Outpatient Pavilion - Hillcrest

San Diego, California, 92103

Not Yet Recruiting

UC San Diego Medical Center - Hillcrest

San Diego, California, 92103

Not Yet Recruiting

UC San Diego Medical Center - Rancho Bernardo

San Diego, California, 92127

Not Yet Recruiting

City of Hope UPLAND

Upland, California, 91786

Recruiting

UC San Diego Medical Center - Vista

Vista, California, 92081

Not Yet Recruiting

Rocky Mountain Cancer Centers, LLP

Denver, Colorado, 80218

Recruiting

Mayo Clinic Pharmacy

Jacksonville, Florida, 32224

Not Yet Recruiting

Tennessee Oncology, PLLC- Ringgold

Ringgold, Georgia, 30736

Not Yet Recruiting

City Of Hope - Chicago

Zion, Illinois, 60099

Recruiting

Brigham and Women's Hospital

Boston, Massachusetts, 02115

Not Yet Recruiting

Dana-Farber Cancer Institute

Boston, Massachusetts, 02215

Not Yet Recruiting

Dana-Farber Cancer Institute - Chestnut Hill

Newton, Massachusetts, 02467

Not Yet Recruiting

Minnesota Oncology Hematology, P.A.

Burnsville, Minnesota, 55337

Recruiting

Minnesota Oncology Hematology, P.A.

Chaska, Minnesota, 55318

Recruiting

Minnesota Oncology Hematology, P.A.

Coon Rapids, Minnesota, 55433

Recruiting

Minnesota Oncology Hematology, P.A.

Edina, Minnesota, 55435

Recruiting

Minnesota Oncology Hematology, P.A.

Maple Grove, Minnesota, 55369

Recruiting

Minnesota Oncology Hematology, P.A.

Maplewood, Minnesota, 55109

Recruiting

Mayo Clinic Hospital, Methodist Campus, Research Pharmacy

Rochester, Minnesota, 55902

Not Yet Recruiting

Mayo Clinic Cancer Center Outpatient Pharmacy

Rochester, Minnesota, 55905

Not Yet Recruiting

Minnesota Oncology Hematology, P.A.

Woodbury, Minnesota, 55125

Recruiting

MSK Basking Ridge

Basking Ridge, New Jersey, 07920

Recruiting

MSK Monmouth

Middletown, New Jersey, 07748

Recruiting

MSK Bergen

Montvale, New Jersey, 07645

Recruiting

New York Oncology Hematology, P.C.

Albany, New York, 12206

Recruiting

New York Oncology Hematology - Clifton Park Cancer Center

Clifton Park, New York, 12065

Recruiting

MSK Commack

Commack, New York, 11725

Recruiting

MSK Westchester

Harrison, New York, 10604

Recruiting

Memorial Sloan Kettering Cancer Center - Investigational Drug Service Pharmacy

Long Island City, New York, 11101

Recruiting

Evelyn H. Lauder Breast and Imaging Center (BAIC)

New York, New York, 10065

Recruiting

Memorial Sloan Kettering Cancer Center - Main Campus

New York, New York, 10065

Recruiting

Sidney Kimmel Center for Prostate and Urological Cancers - Memorial Sloan Kettering Cancer Center

New York, New York, 10065

Recruiting

MSK Nassau

Uniondale, New York, 11553

Recruiting

Grand Strand Medical Center

Myrtle Beach, South Carolina, 295724607

Recruiting

Carolina Urologic Research Center, LLC

Myrtle Beach, South Carolina, 29572

Recruiting

Parkway Surgery Center

Myrtle Beach, South Carolina, 29572

Recruiting

Tennessee Oncology, PLLC- Chattanooga Downtown

Chattanooga, Tennessee, 37403

Not Yet Recruiting

Tennessee Oncology, PLLC - Chattanooga Med Park II

Chattanooga, Tennessee, 37404

Not Yet Recruiting

Tennessee Oncology, PLLC - Chattanooga Memorial

Chattanooga, Tennessee, 37404

Not Yet Recruiting

Tennessee Oncology, PLLC - Investigational Drug Services/Supply Storage

Chattanooga, Tennessee, 37404

Not Yet Recruiting

Tennessee Oncology, PLLC- Chattanooga East

Chattanooga, Tennessee, 37421

Not Yet Recruiting

Tennessee Oncology, PLLC- Cookeville

Cookeville, Tennessee, 38501

Not Yet Recruiting

Tennessee Oncology, PLLC-Dickson

Dickson, Tennessee, 37055

Not Yet Recruiting

Tennessee Oncology, PLLC- Franklin Proton Center

Franklin, Tennessee, 37067

Not Yet Recruiting

Tennessee Oncology, PLLC-Franklin

Franklin, Tennessee, 37067

Not Yet Recruiting

Tennessee Oncology, PLLC-Gallatin

Gallatin, Tennessee, 37066

Not Yet Recruiting

Tennessee Oncology, PLLC-Hendersonville

Hendersonville, Tennessee, 37075

Not Yet Recruiting

Tennessee Oncology, PLLC-Lebanon

Lebanon, Tennessee, 37090

Not Yet Recruiting

Tennessee Oncology, PLLC-Mount Juliet

Mount Juliet, Tennessee, 37122

Not Yet Recruiting

Tennessee Oncology, PLLC-Murfreesboro

Murfreesboro, Tennessee, 37129

Not Yet Recruiting

Sarah Cannon Research Institute

Nashville, Tennessee, 37203

Recruiting

SCRI Oncology Partners

Nashville, Tennessee, 37203

Recruiting

Tennessee Oncology, PLLC- Elliston Place Plaza

Nashville, Tennessee, 37203

Not Yet Recruiting

Tennessee Oncology, PLLC-Elliston Place Plaza Medical Oncology &Hematology

Nashville, Tennessee, 37203

Not Yet Recruiting

Tennessee Oncology, PLLC-Investigational Drug Services

Nashville, Tennessee, 37203

Not Yet Recruiting

Tennessee Oncology, PLLC- Saint Thomas West

Nashville, Tennessee, 37205

Not Yet Recruiting

Tennessee Oncology, PLLC- Skyline

Nashville, Tennessee, 37207

Not Yet Recruiting

Tennessee Oncology, PLLC- Southern Hills

Nashville, Tennessee, 37211

Not Yet Recruiting

Tennessee Oncology, PLLC- Shelbyville

Shelbyville, Tennessee, 37160

Not Yet Recruiting

Tennessee Oncology, PLLC- Smyrna

Smyrna, Tennessee, 37167

Not Yet Recruiting

Texas Oncology - Central South

Austin, Texas, 78705

Recruiting

Texas Oncology - Central South

Austin, Texas, 78731

Recruiting

Texas Oncology - Central South

Austin, Texas, 78745

Recruiting

Texas Oncology - Central South

Austin, Texas, 78758

Recruiting

Texas Oncology - Gulf Coast

Beaumont, Texas, 77702

Recruiting

Texas Oncology - Central South

Harlingen, Texas, 78550

Recruiting

Texas Oncology - Gulf Coast

Houston, Texas, 77024

Recruiting

Texas Oncology - Gulf Coast

Houston, Texas, 77054

Recruiting

US Oncology Investigational Products Center (IPC)

Irving, Texas, 75063

Recruiting

US Oncology Investigational Products Center

Irving, Texas, 75063

Recruiting

Texas Oncology - Central South

McAllen, Texas, 78503

Recruiting

Texas Oncology - Gulf Coast

Pearland, Texas, 77584

Recruiting

Texas Oncology - Gulf Coast

Sugar Land, Texas, 77479

Recruiting

Texas Oncology - Gulf Coast

The Woodlands, Texas, 77380

Recruiting

Texas Oncology - Central South

Waco, Texas, 76712

Recruiting

Texas Oncology - Gulf Coast

Webster, Texas, 77598

Recruiting

Texas Oncology - Central South

Weslaco, Texas, 78596

Recruiting

Oncology & Hematology Associates of Southwest Virginia, Inc., DBA Blue Ridge Cancer Care

Blacksburg, Virginia, 24060

Recruiting

Virginia Cancer Specialists, PC

Fairfax, Virginia, 22031

Recruiting

Oncology & Hematology Associates of Southwest Virginia, Inc., DBA Blue Ridge Cancer Care

Low Moor, Virginia, 24457

Recruiting

Oncology & Hematology Associates of Southwest Virginia, Inc., DBA Blue Ridge Cancer Care

Roanoke, Virginia, 24014

Recruiting

Oncology & Hematology Associates of Southwest Virginia, Inc., DBA Blue Ridge Cancer Care

Salem, Virginia, 24153

Recruiting

Oncology & Hematology Associates of Southwest Virginia, Inc., DBA Blue Ridge Cancer Care

Wytheville, Virginia, 24382

Recruiting

Northwest Cancer Specialists, P.C.

Vancouver, Washington, 98684

Recruiting

Minnesota Oncology Hematology, P.A.

Hudson, Wisconsin, 54016

Recruiting